In this review:
- BEATcc: first-line atezolizumab + platinum doublet + bevacizumab in advanced cervical cancer
- INTERLACE: QoL results
- MoST-CIRCUIT: nivolumab + ipilimumab in advanced gynaecological clear-cell cancers
- KEYNOTE-A18: OS results
- KEYNOTE-B21: pembrolizumab + adjuvant chemotherapy ± radiotherapy in high-risk endometrial cancer
- TROPHAMET: first-line avelumab + methotrexate for low-risk gestational trophoblastic tumours
- ICON9: maintenance olaparib ± cediranib in recurrent platinum sensitive ovarian cancer
- PRIMA: final OS results
- ATHENA-COMBO: first-line maintenance rucaparib + nivolumab vs. rucaparib monotherapy for ovarian cancer
- ATALANTE: final 5-year OS results
Please login below to download this issue (PDF)